The effects of intravesical chemoimmunotherapy with gemcitabine and bacillus Calmette-Guérin in superficial bladder cancer: A preliminary study

Journal of International Medical Research

Volumn 37, Issue 6, 2009, Pages 1823-1830

  Cho, D Y ^a   Bae, J H ^a   Moon, D G ^a   Cheon, J ^a   Lee, J G ^a   Kim, J J ^a   Yoon, D K ^a   Park, Hong Seok ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

BCG; Gemcitabine; Intravesical chemoimmunotherapy; Recurrence rate; Superficial bladder cancer

Indexed keywords

BCG VACCINE; GEMCITABINE;

ADULT; ALOPECIA; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROL GROUP; CONTROLLED STUDY; DYSURIA; FEMALE; FEVER; HAIR LOSS; HEMATURIA; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; NEUTROPENIA; PROSPECTIVE STUDY; RECURRENCE RISK; SIDE EFFECT; SUPERFICIAL CANCER; TRANSURETHRAL RESECTION; TREATMENT DURATION; URINARY FREQUENCY;

EID: 74949099046     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000903700618     Document Type: Article

References (18)

1. Gontero P, Marini L, Frea B: Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option. BJU Int 2005; 96: 970-976.
2. Oosterlinck W, Lobel B, Jakse G, et al: Guidelines on bladder cancer. Eur Urol 2002; 41: 105-112.
3. Heney NM, Nocks BN, Daly JJ, et al: Prognostic factors in carcinoma of the ureter. J Urol 1981; 125: 632-636.
4. Klan R, Loy V, Huland H: Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol 1991; 146: 316-318.
5. Lamm DL: Complications of bacillus Calmette-Guérin immunotherapy. Urol Clin North Am 1992; 19: 565-572.
6. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
7. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
8. Chopin DK, Gattegno B: Superficial bladder tumors. Eur Urol 2002; 42: 533-541.
9. Solsona E, Iborra I, Ricós JV, et al: Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 1999; 161: 1120-1123.
10. Lamm DL: Intravesical therapy for superficial bladder cancer: slow but steady progress. J Clin Oncol 2003; 21: 4259-4260.
11. Böhle A, Jocham D, Bock PR: Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal metaanalysis of comparative studies on recurrence and toxicity. J Urol 2003; 169: 90-95.
12. Huncharek M, Kupelnick B: Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation. Am J Clin Oncol 2003; 26: 402-407.
13. Krege S, Giani G, Meyer R, et al: A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating clinics. J Urol 1996; 156: 962-966.
14. van der Meijden AP, Sylvester RJ, Oosterlinck W, et al for the EORTC Genito-Urinary Tract Cancer Group: Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer genito-urinary group phase III trial. Eur Urol 2003; 44: 429-434.
15. Lamm DL, Blumenstein BA, Crissman JD, et al: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163: 1124-1129.
16. Gontero P, Frea B: Actual experience and future development of gemcitabine in superficial bladder cancer. Ann Oncol 2006; 17: 123-128.
17. Konety BR, Williams RD: Superficial transitional (Ta/T1/CIS) cell carcinoma of the bladder. BJU Int 2004; 94: 18-21.
18. Hendricksen K, Witjes JA: Intravesical gemcitabine: an update of clinical results. Curr Opin Urol 2006; 16: 361-366.